


What Is Claimed Is:

1. A compound of Formula I:



Formula I



wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) and that no more than two of W, X, Y and Z are N;

wherein R₃, R₄, R₅ and R₆ are each independently hydrogen, hydroxy, sulfhydryl, lower alkoxy (1-4 carbon atoms), lower thioalkoxy (1-4 carbon atoms), lower alkyl (1-4 carbon atoms), halo, CN, CF₃, NO₂, COOR, or NR₇R₈;


wherein R₇ and R₈ are independently hydrogen or lower alkyl (1-4 carbon atoms);

M is oxygen or sulfur;

A is selected from the group consisting of:



Sub
B1





wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1;
 R_1 and R_2 independently are:
 an alkyl of 1 to 6 carbon atoms,








unsubstituted, mono or polysubstituted phenyl or
 polyaromatic,
 unsubstituted, mono or polysubstituted heteroaromatic,
 with hetero atom(s) N (nitrogen), O (oxygen) and/or S
 (sulfur) or,
 unsubstituted, mono or polysubstituted aralkyl,
 unsubstituted, mono or polysubstituted cyclo or
 polycycloalkyl hydrocarbon, or
 mono or polyheterocycle (3 to 8 atoms per ring) with one
 to four hetero atoms as N (nitrogen), O (oxygen) or S
 (sulfur); and

wherein the substitutions are selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{13}$
- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl



Sub
B'



- $(CH_2)_i$ - tetrazole, and
- polyhydroxy alkyl or cycloalkyl of from 5 to 8 carbon atoms,

Sub,
B

wherein i and j are independently 0, 1, 2,
R₁₃, R₁₄, R₁₅, R₁₆ are each independently hydrogen, lower
alkyl (1-4 carbon atoms), alkaryl of from 7 to 10 carbon
atoms;

5 NR₁₃R₁₄ is also mono or bicyclic ring with one
to four hetero atoms as N,O,S;

provided that when W, X, Y and Z are each C-R₃,
C-R₄, C-R₅ and C-R₆ and R₃, R₄, R₅ and R₆ are hydrogen and

10
$$\text{A is } \text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-$$
 and R₁ is unsubstituted phenyl, then R₂
cannot be unsubstituted phenyl;

further provided that when W, X, Y and Z are
each C-R₃, C-R₄, C-R₅, and C-R₆ and R₃, R₄, R₅ and R₆ are
15 hydrogen or halogen and

$$\text{A is } -\text{NH}-\overset{\text{O}}{\parallel}{\text{C}}-\text{NH}-$$
, and
M is oxygen, and

20 R₂ is unsubstituted or mono substituted phenyl and
wherein substitution is chloro, bromo, butyl, n-butoxy,
iso-butoxy, then R₁ cannot be unsubstituted or mono
substituted phenyl, or unsubstituted naphthyl wherein
substitution is chloro or bromo;

25 furthermore provided that when W, X, Y and Z
are each C-R₃, C-R₄, C-R₅, and C-R₆ and R₃, R₄, R₅ and R₆
are hydrogen or halogen and

30
$$\text{A is } -\text{NH}-\overset{\text{S}}{\parallel}{\text{C}}-\text{NH}-$$
, and
M is oxygen, and

R₁ is unsubstituted phenyl, unsubstituted benzyl,
unsubstituted naphthyl or mono substituted phenyl
wherein substitution is halogen, methyl, n-butyl or
35 methoxy, then R₂ cannot be: a) unsubstituted phenyl; b)
unsubstituted naphthyl; c) unsubstituted benzyl; d) mono





substituted phenyl wherein substitution is halogen, methyl, n-butoxy, iso-butoxy, or methoxy; or e) disubstituted phenyl wherein substitution is methyl.

2. The compound of claim 1 wherein:

W and Y are each independently C-R₃, C-R₅ or N, X and Z are each independently C-R₄ or C-R₆, wherein R₃, R₄, R₅ and R₆ are each independently chlorine, bromine, iodine, carbmethoxy, carboxy, methoxy, methyl, thio, thiomethyl, thioethyl, and hydroxy;

M is O or S;

A is selected from



wherein R₁₁ and R₁₂ are independently hydrogen or alkyl of from 1 to 4 carbon atoms, n is 0 or 1;

R₁ and R₂ are independently an unsubstituted, mono or polysubstituted

Sub B'
phenyl,
pyridyl,
pyrrolyl,
furanyl,
5 thiofuranyl,
pyrimidinyl,
indolyl,
quinolinyl,
quinaxolinyl; or

10 a cyclo or polycycloalkyl hydrocarbon of 6 to 12 carbon atoms;

wherein the substituents are of claim 1, having up to three substituents per ring.

3. The compound of claim 1 wherein:

15 W is C-R₃ or N wherein R₃ is selected from hydrogen, chlorine, bromine, iodine, methoxy, and methyl;


20 X is C-R₄ wherein R₄ is selected from hydrogen, chlorine, hydroxy, methoxy, sulfhydryl and thioethyl-ether;

Y is C-R₅ wherein R₅ is selected from hydrogen, chlorine, bromine, iodine, methoxy, methyl, carboxy, and carbmethoxy;





Z is C-R₆ and N, wherein R₆ is hydrogen;

25 M is oxygen or sulfur;

A is selected from



Sub
B1



wherein R_{11} and R_{12} are hydrogen;
 n is 0 or 1;


R_1 and R_2 are independently phenyl,
mono or polysubstituted phenyl,
25 pyridyl,
pyrrolyl,
furanyl,
thiofuranyl,
pyrimidinyl,
30 indolyl,
quinolinyl,
quinaxolinyl;

wherein substitutions are the same as in claim
1.

4. The compound of claim 1 wherein:


M is sulfur,

A is




and W, X, Y, Z, R₁ and R₂ are as in claim 1.

5. The compound of claim 4 having the structure:




6. The compound of claim 4 having the structure:



7. The compound of claim 1 wherein:

M is oxygen;

A is




Sub
B.2

W, X, Y, and Z are selected from C-R₃, C-R₄, C-R₅, C-R₆ and N and at least one and no more than two of W, X, Y and Z are N. R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1.

C

5


8. The compound of claim 54 having the structure:



B

C


9. The compound of claim 54 having the structure:



B

Sub
B3

10. The compound of claim 1 having the structure:



wherein R_x is hydroxy, sulfhydryl, lower alkoxy (1-4 carbon atoms), lower thioalkoxy (1-4 carbon atoms), lower alkyl (1-4 carbon atoms), halo, CN, CF_3 , NO_2 , $COOR$, or NR_xR_y , where $x=0-3$;

wherein R_7 and R_8 are independently hydrogen or lower alkyl (1-4 carbon atoms);


R_1 and R_2 are as defined in Formula I.

11. The compound of claim 1 wherein:

W , X , Y and Z are selected from $C-R_3$, $C-R_4$, $C-R_5$ and $C-R_6$;

M is oxygen;

A is




R_1 and R_2 cannot both be phenyl in the same compound; and R_3 , R_4 , R_5 and R_6 are as defined in claim 1.

12. The compound of claim 1 wherein:


M is S (sulfur);

20 W , X , Y , Z , R_1 and R_2 are as defined in claim 1; and

A is



having the structure:




13. The compound of claim 1 wherein:

W, X, Y and Z are selected from C-R₃, C-R₄, C-R₅, C-R₆ and N and at least one and no more than two W, X, Y and Z are N;


R₁, R₂, R₃, R₄, R₅ and R₆ are as defined in claim 1;

M is oxygen; and

A is



having the structure:



14. The compound of claim 1 wherein:

W, X, Y and Z are selected from C-R₃, C-R₄, C-R₅, and C-R₆ wherein R₃, R₄, R₅ and R₆ are as defined in claim 1 except none can be hydrogen or halogen;

M is oxygen;

Sub B4

A is
$$\begin{array}{c} \text{S} \\ || \\ -\text{NH}-\text{C}-\text{NH}- \end{array}, \text{ and}$$

 R_1 and R_2 are as defined in claim 1.

5 15. The compound of claim 1 wherein:
W, X, Y and Z are selected from C- R_3 , C- R_4 , C- R_5 , C- R_6 ,
wherein R_3 , R_4 , R_5 and R_6 are independently selected from
hydrogen and halogen;
M is oxygen;

10 A is
$$\begin{array}{c} \text{S} \\ || \\ -\text{NH}-\text{C}-\text{NH}- \end{array}.$$

Sub B5

15 16. The compound of claim 1 wherein:
W, X, Y, and Z are each independently selected
from C- R_3 , C- R_4 , C- R_5 , C- R_6 and wherein R_3 , R_4 , R_5 and R_6
are independently selected from hydroxy, sulfhydryl,
lower alkoxy, lower thioalkoxy, lower alkyl, CN, CF₃,
NO₂, COOR₇, NR₈, wherein R_7 and R_8 are as defined in
claim 1;

20 M is oxygen; and
 R_1 and R_2 are as defined in claim 1.


25 17. The compound of claim 1 wherein:
W, X, Y and Z are each independently selected
from C- R_3 , C- R_4 , C- R_5 , C- R_6 and wherein R_3 , R_4 , R_5 and R_6
are as defined above but they cannot be hydrogen or
halogen;

30 M is oxygen;
A is
$$\begin{array}{c} \text{O} \\ || \\ -\text{NH}-\text{C}-\text{NH}- \end{array}; \text{ and}$$

 R_1 and R_2 are as defined in claim 1.

18. The compound of claim 1 wherein:


- R_{13} and R_{14} are each independently methyl, ethyl, t-butyl,
- R_{15} and R_{16} are each independently methyl, and
- $NR_{13}R_{14}$ is selected from:




where R_{17} is alkyl of 1 to 3 carbon atoms.

19. The compound of claim 1 wherein:


A is



R_1 is



or



R_{13} and R_{14} are each independently selected from hydrogen, methyl, ethyl, t-butyl, and benzyl;

wherein R_{15} and R_{16} are independently selected from hydrogen, methyl and ethyl;

i is 0 or 1;

M is O (oxygen); and


W, X, Y, Z and R_2 are as defined in claim 1.

Sub
B 6

10

15

20. The compound ~~of claim 1~~ having the structure and meanings for R as indicated:



wherein R is selected from the group consisting of:

- a) 4-BrPh;
- b) 4-COOEt-Ph;
- c) 4-CF₃Ph;
- d) 3-Me-Ph;
- e) 3,5-dichloro-4-pyridinyl;
- f) 3-COOEt-Ph;
- g) 3-COOtBu-Ph;
- h) 3-COOH-Ph;
- i) 4-MeO-Ph;
- j) 3-MeO-Ph;
- k) 2-MeO-Ph; and
- l) C₆H₅.

21. The compound of ~~claim 1~~⁵⁰ is selected from:
Hydrazinecarboxamide, N-(4-bromophenyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-;

Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]-carbonyl]amino]-ethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(4-methoxyphenyl)-;

5 Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methoxyphenyl)-;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(2-methoxyphenyl)-;

10 Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-[(4-trifluoromethyl)phenyl]-;

15 Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, 1,1-dimethylethyl ester;

Hydrazinecarboxamide, 2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]-N-(3-methylphenyl)-;

B
B
20 Hydrazinecarboxamide, N-(3,5-^{dichloro}~~dichloro~~-4-pyridinyl)-2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl];

Benzoic acid, 4-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]- ethyl ester;

25 Benzoic acid, 2-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-, ethyl ester; and

30 Benzoic acid, 3-[[[2-[3,4-dihydro-3-[3-(1-methylethoxy)phenyl]-4-oxo-2-quinazolinyl]hydrazino]carbonyl]amino]-.

Sub B.7
22. The compound of Claim 1 is selected from the group consisting of:

2-Thioxo-3-o-tolyl-2,3-dihydro-1H-quinazolin-4-one

3-(2-Ethyl-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(4-Chloro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(2,3-Dichloro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(3-Fluoro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-Naphthalen-1-yl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(3-Methoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

2-Hydrazino-3-(3-methoxy-phenyl)-3H-quinazolin-4-one

3-(3-Dimethylamino-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-[4-(Morpholine-4-sulfonyl)-phenyl]-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-Pyridin-3-yl-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(4-Methoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(3-Nitro-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

3-(3-Isopropoxy-phenyl)-2-thioxo-2,3-dihydro-1H-pyrido[2,3-d]pyrimidin-4-one

3-(3,4-Dimethoxy-phenyl)-2-thioxo-2,3-dihydro-1H-quinazolin-4-one

23. The compound of Claim 1 is selected from the group consisting of:

2-Hydrazino-3-o-tolyl-3H-quinazolin-4-one

3-(2-Ethyl-phenyl)-2-hydrazino-3H-quinazolin-4-one

Sub
B. 7








- 3- (4-Chloro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3- (2,3-Dichloro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3- (3-Fluoro-phenyl) -2-hydrazino-3H-quinazolin-4-one
2-Hydrazino-3-naphthalen-1-yl-3H-quinazolin-4-one
5 2-Hydrazino-3- (3-methoxy-phenyl) -3H-quinazolin-4-one
3- (3-Fluoro-phenyl) -2-hydrazino-3H-quinazolin-4-one
3- (3-Dimethylamino-phenyl) -2-hydrazino-3H-quinazolin-4-
-one
2-Hydrazino-3- [4- (morpholine-4-sulfonyl) -phenyl] -3H
10 -quinazolin-4-one
2-Hydrazino-3-pyridin-3-yl-3H-quinazolin-4-one
2-Hydrazino-3- (4-methoxy-phenyl) -3H-quinazolin-4-one
3- (3-Amino-phenyl) -2-hydrazino-3H-quinazolin-4-one
2-Hydrazino-3- (3-isopropoxy-phenyl) -3H-pyrido[2,3
15 -d]pyrimidin-4-one
3- (3,4-Dimethoxy-phenyl) -2-hydrazino-3H-quinazolin-4-one

24. The compound of Claim 1 wherein R₂ is
unsubstituted, mono or polysubstituted phenyl or
polyaromatic,
20 unsubstituted, mono or polysubstituted heteroaromatic,
with hetero atom(s) N (nitrogen), O (oxygen) and/or S
(sulfur) or,
unsubstituted, mono or polysubstituted aralkyl,
unsubstituted, mono or polysubstituted cyclo or
25 polycycloalkyl hydrocarbon, or
mono or polyheterocycle (3 to 8 atoms per ring) with one
to four hetero atoms as N (nitrogen), O (oxygen) or S
(sulfur); and
wherein the substitutions are selected from
30 - hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂)_iOR₁₃
- (CH₂)_iSR₁₃

Sub
B7



5

- trifluoromethyl
- nitro
- halo
- cyano
- azido
- acetyl




, and

Sub
B7




B C

25. The compound of Claim ~~21~~²⁴ wherein R_2 is




wherein $-NR_{13}R_{14}$ is selected from



wherein R_{17} is alkyl of 1 to 3 carbon atoms.

Sub
B8

26. A compound having the structure:





Sub
B8

wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) wherein no more than two of W, X, Y and Z are N;

M is oxygen or sulfur;

5 A is selected from the group consisting of:





15 wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1 ;

R_1 , R_3 , R_4 , R_5 , R_6 , R_7 , and R_8 are as defined in claim 1; and

R_{17} is an alkyl of 1 to 3 carbon atoms.

27. The compound of claim ⁶²~~26~~ wherein

20 A is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{NH}-\text{C}-\text{NH}- \end{array}$; and
M is oxygen.

25 28. The compound of claim ⁶²~~26~~ wherein W, X, Y and Z are each independently selected from C- R_3 , C- R_4 , C- R_5 and C- R_6 ,

30 A is $\begin{array}{c} \text{O} \\ \parallel \\ -\text{NH}-\text{C}-\text{NH}- \end{array}$;
M is oxygen; and
 R_{17} is i-propyl.

62

29. The compound of claim ~~26~~ wherein W, X, Y and Z are each independently selected from C-R₃, C-R₄, C-R₅ and C-R₆ and R₃, R₄, R₅ and R₆ are hydrogen,




5 A is $\text{—NH—}\overset{\text{O}}{\underset{\parallel}{\text{C}}}\text{—NH—};$





M is oxygen;

R₁₇ is i-propyl;

10 R₁ is mono or polysubstituted phenyl wherein substitution is selected from

- hydrogen
- lower alkyl of 1-4 carbon atoms,
- (CH₂)_iOR₁₃
- (CH₂)_iSR₁₃
- 15 - trifluoromethyl
- nitro
- halo
- cyano
- azido
- 20 - acetyl





- $(CH_2)_i$ - tetrazole, and
- polyhydroxy alkyl or cycloalkyl of from 5 to 8 carbon atoms,


wherein i and j are independently 0, 1, 2,

- 5 R_{13} , R_{14} , R_{15} , R_{16} are each independently hydrogen, lower alkyl (1-4 carbon atoms), alkaryl of from 7 to 10 carbon atoms; and

$NR_{13}R_{14}$ is also mono or bicyclic ring with one to four hetero atoms as N,O,S.

- 10 ~~30. A pharmaceutical composition comprising an effective therapeutic amount of the compound of Formula I and a pharmaceutically acceptable salt thereof~~

with a pharmaceutically acceptable carrier in unit dosage form:



Formula I



wherein W, X, Y and Z are each independently selected
5 from C-R₃, C-R₄, C-R₅, C-R₆ and N (nitrogen) and that no more than two of W, X, Y and Z are N;


wherein R₃, R₄, R₅ and R₆ are each independently
hydrogen, hydroxy, sulfhydryl, lower alkoxy (1-4 carbon
atoms), lower thioalkoxy (1-4 carbon atoms), lower alkyl
10 (1-4 carbon atoms), halo, CN, CF₃, NO₂, COOR₇, or NR₇R₈;

wherein R₇ and R₈ are independently hydrogen or
lower alkyl (1-4 carbon atoms);

M is oxygen or sulfur;

A is selected from the group consisting of:





wherein R_{11} and R_{12} are independently hydrogen or lower alkyl (1-4 carbon atoms); $n = 0$ or 1;

R_1 and R_2 independently are:

an alkyl of 1 to 6 carbon atoms,
unsubstituted, mono or polysubstituted phenyl or
polyaromatic,








5 unsubstituted, mono or polysubstituted heteroaromatic,
with hetero atom(s) N (nitrogen), O (oxygen) and/or S
(sulfur) or,

unsubstituted, mono or polysubstituted aralkyl,
unsubstituted, mono or polysubstituted cyclo or

10 polycycloalkyl hydrocarbon, or
mono or polyheterocycle (3 to 8 atoms per ring) with one
to four hetero atoms as N (nitrogen), O (oxygen) or S
(sulfur); and

wherein the substitutions are selected from

- 15 - hydrogen
- lower alkyl of 1-4 carbon atoms,
- $(CH_2)_iOR_{13}$
- $(CH_2)_iSR_{13}$
- trifluoromethyl
20 - nitro
- halo
- cyano
- azido
- acetyl



wherein i and j are independently 0, 1, 2,
R₁₃, R₁₄, R₁₅, R₁₆ are each independently hydrogen, lower
alkyl, alkaryl of from 7 to 10 carbon atoms; and

NR₁₃R₁₄ is also mono or bicyclic ring with one
5 to four hetero atoms as N,O,S.

31. A method for treating a condition advantageously affected by the binding of a compound of Formula I to a CCK receptor in a mammal in need of such treatment comprising providing an effective binding
10 amount of the compound of Formula I according to claim 30.

32. A method of suppressing appetite in a mammal, comprising administering an effective appetite
15 suppressing amount to a mammal in need thereof a compound of Formula I according to claim 30.

33. A method of reducing gastric acid secretion in a mammal comprising administering an effective
20 gastric acid secretion reducing amount to a mammal in need thereof a compound of Formula I according to claim 30.

34. A method of reducing anxiety in a mammal, comprising administering an effective anxiety reducing
amount to a mammal in need thereof a compound of Formula I according to claim 30.

35. A method for treating gastrointestinal
25 ulcers in a mammal comprising administering an effective gastrointestinal ulcer treating amount to a mammal in need thereof a compound of Formula I according to claim 30.

36. A method of treating psychosis in a mammal comprising administering an effective psychosis treating amount to a mammal in need thereof a compound of Formula I according to claim 30.

5 37. A method of blocking drug or alcohol withdrawal reaction in a mammal comprising administering an effective withdrawal reaction blocking amount to a mammal in need thereof a compound of Formula I according to claim 30.

10 38. A method of treating pain in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I according to claim 30.

15 39. A method of treating and/or preventing panic in a mammal comprising administering an effective amount to a mammal in need thereof a compound of Formula I according to claim 30.

20 40. A method of diagnosis of gastrin-dependent tumors in a mammal, comprising administering to the mammal in need thereof an effective diagnosing amount of a radiolabelled iodo compound of Formula I of claim 30.

add
B9
add
C1